Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of significant cardiac disease
Michael I. Kulick(LAC+USC Medical Center), Anil K. Bhandari(LAC+USC Medical Center), J. Nathan Rubin(LAC+USC Medical Center), Robert K. Rude(LAC+USC Medical Center), Shahbudin H. Rahimtoola(Northwestern University), Robert Hong(LAC+USC Medical Center), Elisabeth Ryzen(LAC+USC Medical Center), Uri Elkayam(Icahn School of Medicine at Mount Sinai)
Cited by 108
Related Papers
The hibernating myocardium
|American Heart Journal|1989|1.3k
Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial
|Journal of the American College of Cardiology|2000|1.1k
Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Peripartum Cardiomyopathy: A Position Statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy
|European Journal of Heart Failure|2010|1.1k
Guidelines for the Management of Patients With Valvular Heart Disease
|Circulation|1998|1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908